The Centers for Disease Control and Prevention’s own outside advisers will convene a meeting at noon on Thursday to further refine how the Pfizer-BioNTech booster should be administered, culminating in a vote to endorse the shot’s use. That panel is expected to further define who should be considered at “high risk” for severe disease and which occupations should qualify individuals for boosters.
Acting FDA Commissioner Janet Woodcock indicated in a statement that those workers may include health care workers, teachers, day care staff and grocery store workers, among others.
“This pandemic is dynamic and evolving, with new data about vaccine safety and effectiveness becoming available every day,” she said. “As we learn more about the safety and effectiveness of COVID-19 vaccines, including the use of a booster dose, we will continue to evaluate the rapidly changing science and keep the public informed.”
Pfizer Chair and CEO Albert Bourla praised the FDA decision as a “critical milestone” in fighting the pandemic. “We believe boosters have an important role to play in addressing the continued threat of this disease, alongside efforts to increase global access and uptake among the unvaccinated,” he said in a statement.
The Biden administration had hoped to begin a broader booster rollout this week, after top federal health officials endorsed the idea of offering a third dose of the Pfizer-BioNTech and Moderna Covid-19 vaccines to most adults on that timetable. But in the weeks after that announcement, scientists in and out of the federal government pushed back against the idea, arguing there was not convincing evidence for the plan.
Two of FDA’s top vaccine regulators decided to retire from the agency, at least in part over disagreements related to the administration’s booster timeline.
FDA’s vaccine advisory panel threw a wrench in the administration’s original booster plans on Friday when its members rejected the notion of fully approving the Pfizer-BioNTech booster for people 16 and older, citing concerns about the quality of existing data on safety and effectiveness. The panel instead endorsed narrower use of the shot.
FDA granted full approval to the Pfizer-BioNTech vaccine for people 16 and older on Aug. 23. The shot remains available under an emergency use authorization for teens 12 to 15.